Myxomatous Degeneration of the Canine Mitral Valve: From Gross Changes to Molecular Events by Markby, Greg et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myxomatous Degeneration of the Canine Mitral Valve: From
Gross Changes to Molecular Events
Citation for published version:
Markby, G, Summers, K, MacRae, V, Del-Pozo, J & Corcoran, B 2017, 'Myxomatous Degeneration of the
Canine Mitral Valve: From Gross Changes to Molecular Events' Journal of Comparative Pathology, vol 156,
no. 4, pp. 371-383. DOI: 10.1016/j.jcpa.2017.01.009
Digital Object Identifier (DOI):
10.1016/j.jcpa.2017.01.009
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Comparative Pathology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 13. Apr. 2018
 1 
REVIEW ARTICLE 
 
SPONTANEOUSLY ARISING DISEASE 
 
Short Title: Canine Mitral Valve Myxomatous Degeneration 
 
Myxomatous Degeneration of the Canine Mitral Valve: from Gross Changes to 
Molecular Events 
 
G. Markby*, K. M. Summers*, V. E. MacRae*, J. Del-Pozo† and B. M. Corcoran† 
 
*Roslin Institute and †Royal (Dick) School of Veterinary Studies, the University of Edinburgh, 
Easterbush Veterinary Centre, Roslin, Scotland, UK. 
 
 
 
 
 
 
 
Correspondence to: B. M. Corcoran (e-mail: Brendan.Corcoran@ed.ac.uk). 
 2 
Summary 
Myxomatous mitral valve disease (MMVD) is the single most common acquired heart 
disease of the dog, but is also of emerging importance in human medicine, with some features 
of the disease shared between both species.  There has been increased understanding of this 
disease in recent years, with most research aiming to elucidate the cellular and molecular 
events of disease pathogenesis.  For gross and histological changes, much of our 
understanding is based on historical studies and there has been no comprehensive re-appraisal 
of the pathology of MMVD.  This paper reviews the gross, histological, ultrastructural, 
cellular and molecular changes in canine MMVD.  
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Introduction 
Myxomatous mitral valve disease (MMVD) is the most common acquired cardiac disease of 
the dog and is a major cause of morbidity and mortality in this species (Darke, 1987; 
Beardow and Buchanan, 1993; Hamlin et al., 1996; Haggstrom et al., 2004).  Much is known 
about the diagnosis and treatment of MMVD, but only recently has attention focussed on 
better understanding of the pathobiology of this disease.  Recent research builds on original 
pathological studies from more than 30 years ago, and with available molecular tools an 
exciting era of research in canine MMVD is now underway.  While there are similarities with 
human MMVD, there are also clear differences in morphological, genetic and protein 
expression parameters, and extrapolating between species must be done with caution (Hulin 
et al., 2013; Roberts et al., 2014; Thalji et al., 2015).  For example, in human MMVD a large 
component of the pathology is fibrosis, while in canine MMVD, accumulation of a 
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myxomatous substance within the core of the valve is the main change (McDonald et al., 
2002b; Roberts et al., 2014)  
 
Valve Structure 
The mitral valve consists of two leaflets, anterior (septal) and posterior (mitral) and is 
connected to the heart by the annulus fibrosus and to the papillary muscles by the chordae 
tendineae (Fig. 1).  The chordae attach either to the valve edge (first order) or to the 
ventricular surface close to the valve edge (second order).  The latter insertions give a rough 
and irregular surface to the underside of the leaflets, while the atrial surface is smooth.  There 
can be marked variation in chordae/papillary muscle organization, and such variation is 
regarded as normal.  Overall the normal leaflet has a partially translucent appearance and is 
roughly divided into proximal, mid and distal zones, the latter also known as the ‘free edge’.  
Microscopically, each leaflet has an atrial and ventricular surface and a single layer of 
endothelial cells, continuous with that lining the atrium and ventricle, covers each surface 
(Fig. 2).  In the mid-zone there are three identifiable layers, the atrialis, spongiosa and 
fibrosa, each containing varying amounts of collagen I, III, IV and VI, laminin, fibronectin 
and heparan sulphate (Aupperle et al., 2009a).  The thin atrialis is also rich in elastin with a 
mixed amount of scattered collagen fibres and valvular interstitial cells (VICs). The 
spongiosa consists of loose collagen fibres, scattered collagen bundles and small numbers of 
thin elastin fibres embedded in glycosaminoglycan (GAG)-rich ground substance with 
scattered VICs.  Immediately beneath the spongiosa is the dense, well-organized fibrosa layer 
with well-defined collagen bundles and scattered VICs. The fibrosa is continuous with the 
annulus fibrosus and branches off to form the core of the chordae tendineae. The thin 
subendothelial layer on the ventricular side has collagen fibres and occasional elastin, and is 
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suggested to be an additional fourth layer (ventricularis) similar to that seen in the aortic 
valve (Buchanan, 1977; Anderson and Wilcox, 1996; Fox, 2012).  Towards the distal zone 
(free edge) the distinction between spongiosa and fibrosa, at least in some dogs, can become 
indistinct and the valve at this level appears to almost entirely consist of spongiosa covered 
by endothelium (Han et al., 2013b).  Cardiac muscle extends from the atrial myocardium for 
a variable length along the valve leaflets, and while this lessens with age, likely has important 
functional implications in valve mechanics (Culshaw et al., 2010; Fox, 2012).  
 
Gross Pathology 
Gross changes to the leaflets in MMVD are often described according to the Whitney 
classification (Fig. 3), and are graded 0 to 4 with 0 being normal and 4 the most advanced 
form of the disease (Pensinger, 1965; Pomerance and Whitney, 1970; Whitney, 1974; Han et 
al., 2010).  These grades have a close association with advancing age and the intensity of 
cardiac murmur (Han et al., 2010).  Typically, the disease starts with small numbers of 
discrete nodules developing on the free edge of the leaflet with intervening areas of 
translucent leaflet (grade 1), progressing to the development of larger nodules (grade 2), 
coalescence of these nodules (grade 3), involvement of the chordae, and finally, gross 
distortion and ballooning of the leaflets with marked chordal thickening and eventual chordal 
rupture (grade 4).  The main difficulty with grading can be in distinguishing between normal 
and grade 1, and an alternative approach is to use measurement of free-edge thickness as an 
index of severity, but this has not been adopted widely (Disatian et al., 2008, 2010).   
Change in the thickness of the edge of the valve, associated with disease progression, 
has also been confirmed on histological samples, with the posterior leaflet being slightly 
thicker than the anterior (Han et al., 2010).  Additionally, there is lengthening of the valve 
with advancing disease as evidenced by alteration in the ratio of the anterior-to-posterior 
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leaflet length, but the anterior leaflet is always longer than the posterior leaflet, irrespective of 
disease severity (Han et al., 2010).  Chordal changes mirror those seen with the valve proper 
with swelling, thickening and eventual rupture, but chordal changes have not been 
investigated in detail (Fox, 2012). 
 
Microscopical Changes 
On histopathology the most striking changes are expansion of the spongiosa and loss or 
destruction of the fibrosa (Fenoglio and Tuan duc, 1972; Pomerance and Whitney, 1970; 
Whitney, 1974; Buchanan, 1977; Kogure, 1980; Hadian et al., 2007; Han et al., 2010) (Fig. 
4).  The myxomatous changes involve expansion of the loose connective tissue of the 
spongiosa and an increase in amorphous metachromatically-stained mucoid material 
(myxomatous degeneration) (Pensinger, 1965; Pomerance and Whitney, 1970; Buchanan, 
1977; Han et al., 2010).  Amyloid deposition has been reported in a small number of dogs 
with MMVD (Schneider et al., 1971).  The remnants of the fibrosa can be appreciated even in 
advanced disease, but this layer is markedly disorganized (Han et al., 2013b).  Previously, 
these changes had been described as fibro-elastic proliferation, but this does not appear to be 
the case and it is connective tissue disorganization that is the main change (Pensinger, 1965; 
Whitney, 1967; Buchanan, 1977; Aupperle et al., 2009c; Hadian et al., 2009).  Overall, 
depending on the grade of disease, there are changes in laminin, elastin and collagens IV and 
VI in the subendothelium, and elastin, fibronectin and collagens I and II deeper in the leaflet 
(Aupperle et al., 2009c).  In the myxomatous areas there is a measurable reduction in 
connective tissue density and increase in GAG content and this reduction equates with 
disease severity (Han et al., 2010).  An accumulation of fat cells adjacent to the fibrosa and 
mainly towards the valve base has been reported, but may in part be age related (Pomerance 
and Whitney, 1970). 
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Qualitative and quantitative differences in total collagen/connective tissue content 
have been established (Corcoran et al., 2004; Hadian et al., 2007, 2010; Han et al., 2013a). 
There is a reduction in collagen content in lesion areas and these areas tend to be patchy and 
only coalesce into more contiguous areas as the disease progresses (Hadian et al., 2007). 
Changes are typically close to the valve edge and difficult to identify towards the mid and 
basal zone, but image analysis of cell macerated (i.e. valves decellularized with sodium 
hydroxide) scanning electron microscopy images has identified mild changes in the mid-zone 
(Han et al., 2013b).  Overall, there is distinct alteration in collagen bundle orientation and 
fibril alignment in diseased areas (Black et al., 2005; Hadian et al., 2007; Han et al., 2013b). 
There is a reduction in total tissue content (i.e. collagenous and non-collagenous) in 
myxomatous areas and increased expression of GAGs (Hadian et al., 2007; Han et al., 2010).  
Nevertheless, at least in mild to moderate disease, there is a 20% decrease in collagen fibril 
numbers, but only a 10% decrease in total collagen content (Hadian et al., 2010).  
Coupled with these change in collagen there is an increase in immature reducible 
covalent cross-linkage bonds in collagen in affected areas and a reduction in irreducible 
mature cross-linkages (Hadian et al., 2010).  This implies that there is failure to produce 
mature fibrillar collagen to replace normal collagen turnover, and improper collagen 
assembly which can be appreciated at the ultrastructural level (Corcoran et al., 2004; Black et 
al., 2005; Han et al., 2013b). The production of irreducible (mature) cross-linkages requires 
lysyl-oxidase, which is known to become depleted in old age, and therefore, changes are also 
seen as part of the normal ageing process (Eyre et al., 1988; McDonald et al., 2002a, b). 
However, these changes are seen in young dogs and the increased deposition of 
proteoglycans, which is known to occur with MMVD, may interfere with cross-linkages in 
collagen.  The likely involvement of activated myofibroblasts (VICs) in this process, in both 
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the human and canine forms of the disease, is of major interest (Rabkin et al., 2001; Black et 
al., 2005; Disatian et al., 2008; Han et al., 2008).  Similar changes are noted in the chordae 
and include significant reduction in collagen, increase in GAG content and altered GAG 
composition (Buchanan, 1977; Baker et al., 1988).  Fat cell accumulation has been reported 
in the chordae of affected dogs, and is an interesting observation as a change in fat content is 
also reported for the valve base (Ernst et al., 1973b; Buchanan, 1977; Culshaw et al., 2010). 
All of these changes are likely to contribute to the mechanical instability of the entire mitral 
valve complex, and have catastrophic consequences if the chordae rupture. 
 
Cellular Changes 
Interstitial and Stromal Cells 
Cellular changes are noted in diseased canine and human valves (Ernst et al., 1973b; Soini et 
al., 2001; Rabkin-Aikawa et al., 2004; Disatian et al., 2008; Han et al., 2008, 2013a) (Fig. 
5a).  There is an overall decrease in cell numbers in overtly myxomatous zones in the centre 
of the leaflet with a significant increase in cell numbers in the peripheral subendothelial zone 
and close to areas of endothelial cell loss (Han et al., 2010, 2013a, b).  Cell shape does not 
change with advancing disease and the interstitial cells maintain a spindle shape (Han et al., 
2010).  More importantly, there is phenotypic alteration of the valvular interstitial cells from 
a presumed quiescent vimentin-positive fibroblast-like cell to a more activated α-smooth 
muscle actin (α-SMA)-positive cell type (i.e. activated myofibroblasts) (Black et al., 2005; 
Disatian et al., 2008; Han et al., 2008).  The α-SMA-positive cells increase in number and are 
located primarily close to the endothelium, with a partial preference for the atrialis layer 
(Disatian et al., 2008; Han et al., 2008, 2013a).  Increased expression of Ki-67 suggests there 
is cellular proliferation, but what contribution cell migration might make to this is unknown 
(Lu et al., 2016).  The contribution from the endothelium via endothelial-to-mesenchymal 
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transition (EMT) should also be considered, and EMT and recapitulation developmental 
pathways have been partially identified in MMVD (Lu et al., 2015a, 2016).  Throughout the 
diseased valve stroma many cells express embryonic smooth muscle myosin (Smemb), 
another putative marker of myofibroblast activation, while some co-express α-SMA and 
Smemb suggestive of heightened differentiation capacity (Disatian et al., 2008; Lu et al., 
2016).  
VICs can be found in all layers of the valve and may be divided into five identifiable 
phenotypes: (1) embryonic progenitor endothelial/mesenchymal cells, (2) quiescent VICs 
(qVICs), (3) activated VICs (aVICs), (4) progenitor VICs (pVICs), and (5) osteoblastic VICs 
(obVICs) (Liu et al., 2007).  During the earliest stage of valve development, endothelial cells 
invade the endocardial cushion and are transformed into embryonic progenitor 
endothelial/mesenchymal cells, and the cushion undergoes matrix remodelling (Armstrong 
and Bischoff, 2004).  Transforming growth factor (TGF)-β, bone morphogenetic proteins, 
Notch signalling, vascular endothelial growth factor and hyaluronic acid contribute to the 
regulation of this EMT (Choy et al., 1990; Armstrong and Bischoff, 2004; Noseda et al., 
2004; Lu et al., 2015b).  Once the valve is formed, qVICs predominate and are thought to 
maintain valve structure and function and inhibit angiogenesis in the leaflets (i.e. normal life-
long valve remodelling).  The qVICs are then presumed to become activated to aVICs in 
response to disease and injury, and then regulate the pathobiological responses of the valve 
(Liu and Gotlieb, 2007).  Small numbers of desmin-positive VICs with chondroblast 
morphology (obVICs) can be seen in some diseased valves, but calcification is not a clearly 
identified feature of mitral valve disease in the dog (Han et al., 2008).  However, α-SMA-
positive cells can be located in the proximal and mid zones of normal and mildly-affected 
valves, but only begin to appear in large number in the distal zone as disease develops (Lu, 
personal communication).  In diseased valves, a re-emergence of EMT has been identified, 
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with changes in expression of a range of genes associated with valve development and EMT. 
This is best exemplified by emerging co-expression of hyaluronic acid synthase (HAS)-2 and 
α-SMA in endothelial cells, and in the stroma, reduced CDH5 gene expression and increased 
expression of HAS-2 with stromal deposition of hyaluronic acid (Lu et al., 2015a).  Similar 
differentiation capacity has been identified in ovine mitral and porcine aortic valve 
endothelial cells (Bischoff and Aikawa, 2011; Wylie-Sears et al., 2011; Mahler et al., 2013). 
Furthermore, in diseased valves a population of von Willebrand factor (vWF)-positive cells 
can be identified in the stroma, which might be endothelial in origin (Lu et al., 2016). 
Irrespective of their origin or lineage, aVICs are found to lie in areas of loose collagen 
bundles and can be seen to exude fibrillar collagen on electron microscopy, with many 
localized away from the central myxomatous areas and close to the valve edge (Ernst et al., 
1973a, 1974a, b; Black et al., 2005).  This change in cell phenotype and localization 
coincides with disease progression with demonstrable temporal and spatial alteration in valve 
cellularity (Disatian et al., 2008; Han et al., 2008; Lu et al., 2016). However, the increased 
numbers of Smemb-positive cells in the spongiosa, and to a lesser extent the fibrosa, suggests 
distribution of activated myofibroblasts throughout the entire depth of the valve (Disatian et 
al., 2008).  The relative contributions of these two activated myofibroblast subpopulations to 
the overall disease process are unknown.  What is interesting is that the Smemb-positive cells 
show much greater expression of 5-hydroxytryptamine (HT) compared with α-SMA-positive 
cells, considering the putative role of 5-HT/TGF-β signalling in disease pathogenesis 
(Disatian et al., 2008).  In the more advanced stages of the disease, interstitial cells can 
appear more like smooth muscle, form syncytia and anchor to collagen bundles, and this has 
been suggested to compensate for the reduction in valve tensile strength (Ernst et al., 1974b; 
Black et al., 2005).  Coupled with this regionalization of stromal cells, there is a reduction in 
cell number in overtly myxomatous areas compared with normal spongiosa, but no further 
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change in cell number as the disease progresses (Ernst et al., 1973a; Han et al., 2008).  
However, in both human and canine mitral valve disease, there is an increase in total cell 
number through the entire depth of the valve (Rabkin et al., 2001; Rabkin-Aikawa et al., 
2004; Disatian et al., 2008).  A confounding factor in interpreting changes in cell number is 
the increased thickness of diseased valves compared with normal, and when cell numbers are 
indexed to area there is a decrease in cell density (Han et al., 2010).  It is clear that there is 
congregation of cells towards the periphery, close to the overlying endothelium and in areas 
of endothelial loss (Disatian et al., 2008; Han et al., 2008, 2013a).  Experimental ovine valve 
injury models show the same effect (Lester et al., 1992, 1993; Black et al., 2005; Han et al., 
2010).  
The exact identity of all of the cells present in myxomatous areas is not known as 
some are both vimentin and α-SMA negative.  However, in diseased valves the majority of 
the cells throughout the valve are Smemb positive and this, coupled with α-SMA expression 
in some cells and their spindle shape, indicates that they mostly have an interstitial phenotype 
(Disatian et al., 2008; Han et al.2008).  In human MMVD, some cells are CD34 and CD117 
positive, suggesting a circulating fibrocyte, mast cell and/or stem cell lineage, but further 
work is needed to determine their precise phenotypes and to see if the same populations occur 
in dogs (Barth et al., 2004, 2005).  In dogs with advanced disease there is evidence of a 
marginal increase in the number of mast cells in affected valves (Han et al., 2008).  However, 
in dogs with severe MMVD there is no evidence of involvement of the resident macrophage 
population in disease pathogenesis, or recruitment of inflammatory cells, as evidenced by the 
lack of expression of CD68, CD11c, CD45 and MAC387, despite increased expression of 
gene transcripts encoding for several inflammatory cytokines and adhesion molecules 
(Disatian et al., 2008; Han et al., 2008; Disatian and Orton, 2009; Lu et al., 2016).  Electron 
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microscopy has also failed to identify inflammatory cells in the stroma of diseased canine 
valves (Ernst et al., 1974b; Black et al., 2005).  
 
Valvular Endothelial Cells  
Changes to the endothelium are clearly seen in MMVD.  Scanning electron microscopy 
demonstrates areas of endothelial loss, cellular pleomorphism and increased numbers of 
surface micro-appendages (Ernst et al., 1973a, 1974b; Corcoran et al., 2004) (Fig. 5b). These 
changes are suggestive of basement membrane abnormalities, endothelial cell death and 
reactive changes in the endothelium in response to insult. Similar changes can be identified 
on transmission electron microscopy, with interstitial cell accumulation in the immediate 
subendothelium and disruption of the basement membrane (Black et al., 2005; Han et al., 
2013a).  Endothelial damage has also been detected using expression of the endothelial cell 
markers CD31 and vWF, with clear reduction of expression of these markers in canine 
MMVD, and further reduction as disease progresses (Disatian et al., 2008; Lu et al., 2016). 
The transition of VECs as part of EMT is also an important change (Lu et al., 2015a). 
It has been hypothesized for many years that repeated damage to the leaflet edge is likely to 
play a role in the aetiopathogenesis of canine MMVD and the localization of lesions to the 
valve edge with demonstrable changes to the endothelium would support that assertion. 
Functional changes in canine valve endothelium have been identified, with increased nitric 
oxide (NO) synthase activity (i.e. expression of NADH, NADPH reductase and diaphorase), 
increased endothelin (ET) receptor expression (associated with severity), subendothelial 
collagen degeneration and deposition of mucopolysaccharides (Ernst et al., 1973b; Mow and 
Pedersen, 1999; Olsen et al., 2003).  This suggests that NO and ET might contribute to the 
development of MMVD, as both have an effect on extracellular matrix production (Olsen et 
al., 2003).  The migration and localization of activated myofibroblasts towards the 
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endothelium in MMVD may be a part of this process and would fit into the endothelial injury 
model of disease pathogenesis (Black et al., 2005; Disatian et al., 2008; Han et al., 2008).     
 
 
Molecular and Biochemical Changes 
Activation of VICs has been shown to be associated with increased extracellular matrix 
(ECM) secretion (Durbin and Gotlieb, 2002).  Several lines of evidence have shown that 
phenotypic alteration in VICs is crucial to the development of myxomatous degeneration and 
probably accounts for the derangement of the valvular ECM seen in both canine MMVD and 
human mitral valve disease (Rabkin et al., 2001; Rabkin-Aikawa et al., 2004; Black et al., 
2005; Disatian et al., 2008; Han et al., 2008). The ECM derangement may in part be due to 
altered expression of matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs), 
the ‘A disintegrin and metalloproteinase with thrombospondin motifs’ (ADAMTS) family of 
metalloproteases and cathepsins (Soini et al., 2001; Rabkin-Aikawa et al., 2004; Aupperle et 
al., 2009a, 2010; Lu et al., 2015c).  In the dog, with advancing valvular disease, there is 
decreased expression of the gelatinase MMP-2, an increase in cell surface-bound MMP-14 
and an increase in TIMP-2 and TIMP-3 expression, illustrating a change in the balance of 
catabolic enzymes and their inhibitors that are important in normal valve remodelling 
(Aupperle et al., 2009b).  Changes in gene expression for the MMPs and TIMPs in both 
human and canine MMVD do not always match that seen on immunohistochemistry, but a 
4.5-fold increase in TIMP-1 has been reported (Oyama and Chittur, 2006; Lu et al., 2015c; 
Greenhouse et al., 2016).  MMP-14 is important in the degradation of collagens I, II and III 
and its presence in the valves of dogs with MMVD, but not in human diseased valves, 
probably reflects a dog-specific alteration in VIC phenotype (Soini et al., 2001; Aupperle et 
al., 2009b).  Mice with cardiac-specific transgenic expression of active MMP-2 have been 
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shown to develop marked mitral valve thickening and prolapse with a major loss of collagen 
bundles and a large accumulation of acidic GAGs, similar to the pathological changes 
observed in canine MMVD (Aupperle et al., 2009b; Mahimkar et al., 2008). MMP substrates 
can also include basement membrane components, and basement membrane loss is seen on 
transmission electron microscopy of diseased dog valves (Matrisian, 1990; Black et al., 2005; 
Han et al., 2013a).  
Gene and protein expression changes implicated in basement membrane disarray have 
been reported, including alterations in expression of genes encoding NID1, LAM1, LAMA2, 
CTSS COL6A3, and the proteins laminin, collagen IV and fibronectin (Aupperle et al., 2009a; 
Lu et al., 2015c).  The cathepsin-encoding genes CTSK and CTSS are significantly 
upregulated in diseased valves and in human MMVD aVICs (Rabkin et al., 2001; Lu et al., 
2015c).  Expression of these genes is induced by a range of inflammatory cytokines, 
including interleukins and tumour necrosis factor (TNF)-α, and the substrates of these 
molecules include elastin, collagens, fibronectin, laminin and nidrogen.  While tissue protein 
expression of the ADAMTS peptidases has not been reported, there are interesting gene 
changes found in both human and canine MMVD (Lu et al., 2015c; Thalji et al., 2015). There 
is significant down-regulation of ADAMTS2, ADAMTS9, ADAMTS19 and ADAMTSL4 in 
diseased canine valves (Lu et al., 2015c).  Additionally, a strain of mice with knockout of the 
gene encoding the proteoglycan cleaving protein ADAMTS5 has been shown to develop a 
MMVD phenotype due to a lack of proteoglycan clearance.  Considering their function in 
pro-collagen maturation, deposition of the small leucine rich proteoglycan (SLRP) versican 
and regulation of fibrillin-1 and elastin production (Marfan syndrome) respectively, these 
changes in ADAMTS gene expression fit in with the known valve pathology.  Of all of the 
catabolic enzymes that might be contributing to the pathology of MMVD, it is study of 
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molecules of the ADAMS family and the cathepsins, but not necessarily the MMPs, which 
might be most informative (Lu et al., 2015c; Greenhouse et al., 2016). 
Alteration in proteoglycan (PG) and GAG expression is also a cardinal feature of 
mitral valve disease, but has been reported to a limited extent in the dog (Ernst et al., 1973b; 
Han et al., 2010).  Increased PG content in canine valves has been extrapolated indirectly by 
using cell maceration scanning electron microscopy (Han et al., 2013b).  Reduction in 
fibrillar connective tissue components in human myxomatous mitral valve disease coincides 
with increased expression of GAGs (Cole et al., 1984; Lis et al., 1987; Whittaker et al., 1987; 
Tamura et al., 1995; Grande-Allen et al., 2003).  However, the relative proportions of the 
different GAGs also changes with age in normal human subjects, and this is a confounding 
factor when considering disease-associated changes in a disease that is age-dependent 
(Murata, 1981; McDonald et al., 2002b).  PGs and GAGs are necessary for the proper 
assembly of the ECM, interact with other important structural proteins such as fibronectin 
and laminin and have a role in elastin fibrogenesis (Fornieri et al., 1987).  Hyaluronic acid is 
the most abundant GAG in mitral valves, but other proteoglycans, particularly the SLRPs, are 
likely to have an equally important role in maintaining a healthy ECM (Radermecker et al., 
2003).  SLRP gene transcripts have the highest signal intensity of all transcripts in normal 
and diseased canine valves and there is significantly decreased expression of CHAD and 
KERA (encoding keratocan) in the canine valve (Lu et al., 2015c).  Keratocan is of particular 
interest as it is important in collagen assembly.  Decorin and biglycan are increased in the 
diseased canine valvular proteome and biglycan, decorin and versican are increased in human 
MMVD valve tissue (Gupta et al., 2008; Lacerda et al., 2009; Radermecker et al., 2003).  
Decorin plays a critical role in collagen fibrillogenesis, while biglycan is found in both 
collagen- and elastin-rich regions and also influences elastic fibre formation (Reinboth et al., 
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2002; Gupta et al., 2008).  The accumulation of GAGs in MMVD is a major contributor to 
valve thickening and contributes to the mechanical failure of the valve (Tamura et al., 1995).  
Elastin is particularly interesting as it has greater tensile strength than collagen and 
may contribute disproportionately to valve mechanical integrity and strength (Tamura et al., 
1995).  An increase in elastic fibres has been reported in human and canine myxomatous 
mitral valves, but the fibres are thinner than normal, arranged into more distinct bundles, and 
the bundles are more widely separated than in normal leaflets (Tamura et al., 1995). 
The signalling pathways that drive all of these structural changes are complex and 
only understood partially.  Global valve tissue transcriptomic profiling has identified a wide 
range of gene changes associated with MMVD in man and dogs (Oyama and Chittur, 2006; 
Hulin et al., 2012; Sainger et al., 2012; Lu et al., 2015c; Thalji et al., 2015; Greenhouse et 
al., 2016).  In human MMVD, further major gene changes include the expression of genes 
involved in control of oxidative stress (an endothelium function) and downregulation of the 
endothelin receptor type A (ET-A) gene EDNRA (Hulin et al., 2012).  In the dog there is 
upregulation of the gene encoding the 5-HT2B receptor, but this is not seen in human 
MMVD.  In contrast, there is greater evidence of activation of TGF-β signaling pathways in 
human MMVD that will drive fibrosis (Hulin et al., 2012; Sainger et al., 2012; Thalji et al., 
2015; Greenhouse et al., 2016).  Changes in TGF-β protein and gene expression have been 
identified in canine MMVD using immunohistochemistry and reverse transcriptase 
polymerase chain reaction for TGF-β1, -2 and -3 and TGF-β2, but transcriptomic profiling 
has not found such changes (Oyama and Chittur, 2006; Aupperle et al., 2008; Obayashi et al., 
2011; Moesgaard et al., 2014; Lu et al., 2015c).  Furthermore, upregulation of members of 
the transcription factor family NFATc is found in human MMVD, but is downregulated in 
the canine transcriptome (Lu et al., 2015c; Greenhouse et al., 2016).  NFATc has an 
important function in the production of ECM.  These canine/human differences are not 
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unexpected considering that fibrosis is not a cardinal feature of canine MMVD (Buchanan, 
1977; Roberts et al., 2014).  
Up-regulation of the 5-HT2B receptor in the dog is an interesting finding as it is 
reminiscent of the pathological change in the valve that occurs with use of the appetite 
suppressant phentermine-fenfluramine and various anti-Parkinsonian drugs (Connolly et al., 
2009).  The 5-HT/TGF-β signalling pathway is important in ECM production, including 
collagen and fibronectin, but 5HT has not been shown to transform VICs into α-SMA-
positive cells, a cardinal feature of MMVD (Connolly et al., 2009; Oyama and Levy, 2010). 
The increased protein expression of the 5-HT2B receptor, the rate limiting enzyme in 
serotonin synthesis tryptophan hydroxylase-1 (primarily in Smemb-positive cells), 
phosphorylated ERK-1 and TGFβ-1 receptors in canine MMVD would support a possible 
role for enhanced serotonin signalling in MMVD (Arndt et al., 2009; Disatian and Orton, 
2009).  However, the downregulation of proteins important for tryptophan hydroxylase 
function may mean that this potential mechanism of disease pathogenesis might not be 
activated, and the exact role of 5HT in the pathogenesis of MMVD is unclear (Lacerda et al., 
2009).  
In the dog, cluster analysis of all gene changes suggests that the most affected 
biologically relevant functions are inflammatory response, cellular movement, cardiovascular 
development, extracellular matrix organization and epithelial-to-mesenchymal transition, as 
well as the endothelial function pathways, caveolar-mediated endocytosis signalling, 
endothelin-1 signalling and epithelial adherens junctions remodelling (Oyama and Chittur, 
2006; Lu et al., 2015c).   Caveolar-mediated endocytosis regulates endothelial cell growth, 
endocytosis and cell migration and reduces TGF-β-induced fibroblast activation (Del Galdo 
et al., 2008; Sowa, 2012).  In canine and human MMVD there is increased expression of 
genes encoding inflammatory molecules such as vascular cell adhesion molecule (VCAM)-1, 
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intercellular adhesion molecule (ICAM)-1, selectin E (SELE), Toll-like receptor (TLR)-4, 
TLR-8, interleukin (IL)-18 and IL-6, which can trigger ECM changes and EMT (Oyama and 
Chittur, 2006; Hulin et al., 2012; Sainger et al., 2012; Mahler et al., 2013; Lu et al., 2015c).  
Activation of low density lipoprotein receptor (LDLR) has been reported in valves affected 
by MMVD, where this molecule is predicted to upregulate expression of a variety of 
inflammatory mediators (Olsen et al., 1999; Lu et al., 2015c).  An experimental mechanical 
endothelial shear stress model has been shown to generate reactive oxygen species that act as 
intracellular secondary messengers and result in elevation of inflammatory cytokines, 
particularly ICAM-1 (Chiu et al., 1997).  The increase in expression of genes encoding IL-6, 
IL-1 and IL-10, as well as the adhesion molecules VCAM-1 and ICAM-1, may represent a 
response to the endothelial damage associated with MMVD (Corcoran et al., 2004; Han et 
al., 2013a).  Upregulation of genes associated with oxidative stress has been identified in 
canine and human MMVD and the increase in inflammation-associated cytokines might be in 
response to reactive oxygen species (ROS) generated by endothelial shear stress (Hulin et al., 
2012; Sainger et al., 2012; Lu et al., 2015c).  All of these gene functions are not unexpected 
considering what is known about valve pathology.  Groups of gene changes, which on first 
examination might not appear to have related functions, clearly contribute to valve pathology 
by affecting VEC function, transition and loss, VIC activation, proliferation and migration, 
catabolism of the ECM and aberrant remodelling of the same, without inducing a fibrotic 
response in the dog.  A similar array of changes, but with subtle differences, illustrate the role 
of fibrosis in human MMVD and the contrast with the canine disease. 
 
Conclusion 
There have been major advances in understanding of the pathobiology of canine MMVD in 
the last 10 years and research activities are ongoing and expanding at various centres.  In 
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addition, there is a large amount of comparative data emerging from studies of human 
MMVD and associated diseases, but caution must be exercised in extrapolating new findings 
between man and the dog.  The availability of dog-specific molecular tools has allowed the 
linking of pathological events to effects at the levels of gene and protein expression.  
However, since the pathological data are more than 30 years old, there is also a need to re-
appraise the morphological changes seen with MMVD at the gross, histological and 
ultrastructural levels.  An observation of the same problems in human MMVD research has 
recently been reported showing that fundamental aspects of valve pathology, particularly the 
fibrotic response, have been over-looked (Roberts et al., 2014). 
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Fig. 1.  Healthy canine mitral valve.  (A) Gross view of the valve after dissection.  Note the 
presence of an anterior leaflet (AL), posterior leaflet (PL) and chordae tendinae (arrows) 
connecting the leaflets to the ventricular papillary muscles (PM).  (B) Subgross view of the 
anterior leaflet of the mitral valve, highlighting its two surfaces (atrial and ventricular), the 
proximal/medial/distal areas, the presence of myocardium extending into the base of the 
valve (*), and the attachment of the chordae tendinae.  Note that all of the chordae included 
are of second order.  Masson’s trichrome.  Bar, 1 mm. 
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Fig. 2.  Healthy canine mitral valve. (A) Images of the same valve at the mid-level displaying 
the histological features of the atrialis (A), spongiosa (S) and fibrosa (F), with three different 
histochemical stains.  Note the endothelial lining on both the atrial and ventricular aspects of 
the leaflet, elastin accumulation in the atrialis (arrows), loose connective tissue of the 
spongiosa and dense collagen of the fibrosa.  Haematoxylin and eosin, Masson’s trichrome 
stain and Miller’s elastin stain.  Bar, 50 m.  (B) A subgross view of the same valve stained 
with Alcian blue highlights the presence of mucopolysaccharide within the leaflet.  Bar, 1 
mm. 
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Fig. 3.  Whitney grading scheme for myxomatous valvular degeneration.  Both the gross and 
histological presentations are illustrated.  Note the location of myxomatous nodules at the tip 
of the mitral leaflets.  There is increase in nodule size with grade, which results in marked 
distortion of the leaflet tip at higher grades.  In grade IV, there is evident thickening of 
chordae tendinae. HE.  Bar, 2 mm. 
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Fig. 4.  Histological changes during myxomatous valvular degeneration.  The atrialis aspect 
of the valves is at the top of the picture.  (A) There is accumulation of alcian blue-positive 
myxomatous substance within the spongiosa and fibrosa layers. Bar, 200 µm.  (B) This 
results in distortion and reduction in density of the fibrosa layer, appreciable with Masson’s 
trichrome stain.  Bar, 200 µm.  (C) With HE staining, the centre of the lesion is characterized 
by accumulation of unstained material between haphazardly arranged bundles of eosinophilic 
material and scattered spindle-shaped interstitial cells.  Bar, 100 µm. 
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Fig. 5.  (A) Representative images of immunohistochemical labelling showing the 
distribution of cells positive for α-smooth muscle actin (α-SMA), embryonic smooth muscle 
myosin (Smemb) and vimentin in mitral valve myxomatous degeneration.  Cells expressing 
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α-SMA are predominantly close to the valve edge surrounding the central myxoid core (cross 
section [left] and longitudinal section [right]; Bar, 1mm).  Smemb has similar distribution, 
but with fewer labelled cells (Bar, 50μm) and vimentin labelling is throughout the valve 
leaflet, but again with increased labelling at the periphery, where there are increased cell 
numbers (Bar, 25μm).  (B) Representative photomicrographs of mitral valve myxomatous 
degeneration showing: endothelial loss and increased endothelial surface micro-appendages, 
with exposure of the valve collagen (upper left, scanning electron microscopy; Bar, 10μm), 
accumulation of α-SMA-positive cells (activated myofibroblasts) close to intact endothelium 
overlying a relatively acellular central myxoid core (upper right, immunohistochemistry 
[IHC]; Bar, 50μm), partial endothelial expression of von Willebrand factor (vWF) (lower left, 
IHC; Bar, 50μm), and endothelial and interstitial expression of zinc-finger protein Snai1 (red) 
with α-SMA also shown (green) (lower right, dual fluorescence immunolabelling; Bar, 
25μm).  
